Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cerebral Adrenoleukodystrophy (CALD): full-pipeline trial registry
2 of 4 indexed Cerebral Adrenoleukodystrophy (CALD) trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Cerebral Adrenoleukodystrophy (CALD): 4 US clinical trials tracked, 2 recruiting.
Cerebral Adrenoleukodystrophy (CALD) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Genetix Biotherapeutics, running 3 of these trials.
Enrollment posture brief
Registry condition cerebral-adrenoleukodystrophy-cald
OPEN 2 | RECR 50% | LATE 1 | EARLY 1 | RANK #4115 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Cerebral Adrenoleukodystrophy (CALD) lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cerebral Adrenoleukodystrophy (CALD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cerebral Adrenoleukodystrophy (CALD) is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel
Genetix Biotherapeutics
NCT06224413
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
Minoryx Therapeutics, S.L.
NCT05819866
Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
Genetix Biotherapeutics
NCT02698579
A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
Genetix Biotherapeutics
NCT01896102
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cerebral Adrenoleukodystrophy (CALD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cerebral Adrenoleukodystrophy (CALD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cerebral Adrenoleukodystrophy (CALD) page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Cerebral Adrenoleukodystrophy (CALD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Genetix Biotherapeutics sponsors the most Cerebral Adrenoleukodystrophy (CALD) trials on record, review their full trial history before evaluating a specific study. See Genetix Biotherapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cerebral Adrenoleukodystrophy (CALD) condition card totals 4 registered trials; most-linked intervention Lenti-D Drug Product (eli-cel); top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.